OncoSec Medical Incorporated Company Profile (NASDAQ:ONCS)

About OncoSec Medical Incorporated (NASDAQ:ONCS)

OncoSec Medical Incorporated logoOncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCS
  • CUSIP: N/A
  • Web: www.oncosec.com
Capitalization:
  • Market Cap: $27.31 million
  • Outstanding Shares: 21,168,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.07
  • 52 Week Range: $0.88 - $2.08
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.23
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.75 per share
  • Price / Book: 1.66
Profitability:
  • EBITDA: ($21,730,000.00)
  • Return on Equity: -101.45%
  • Return on Assets: -84.59%
Debt:
  • Current Ratio: 6.08%
  • Quick Ratio: 6.08%
Misc:
  • Average Volume: 477,832 shs.
  • Beta: 2.53
  • Short Ratio: 14.22
 

Frequently Asked Questions for OncoSec Medical Incorporated (NASDAQ:ONCS)

What is OncoSec Medical Incorporated's stock symbol?

OncoSec Medical Incorporated trades on the NASDAQ under the ticker symbol "ONCS."

How were OncoSec Medical Incorporated's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) issued its quarterly earnings data on Thursday, June, 9th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. View OncoSec Medical Incorporated's Earnings History.

When will OncoSec Medical Incorporated make its next earnings announcement?

OncoSec Medical Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for OncoSec Medical Incorporated.

Where is OncoSec Medical Incorporated's stock going? Where will OncoSec Medical Incorporated's stock price be in 2017?

5 brokerages have issued 1 year price objectives for OncoSec Medical Incorporated's stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate OncoSec Medical Incorporated's share price to reach $5.33 in the next twelve months. View Analyst Ratings for OncoSec Medical Incorporated.

What are analysts saying about OncoSec Medical Incorporated stock?

Here are some recent quotes from research analysts about OncoSec Medical Incorporated stock:

  • 1. HC Wainwright analysts commented, "We believe preliminary interim data—based on the first 16-20 patients—could be reported in late 2017 or early 2018. Management have indicated that an ORR of at least 30% would be considered a success for the PISCES study. We note that positive results from the interim analysis may allow the company to apply for Breakthrough Therapy designation in patients who have failed anti- PD-1 monotherapies. In addition, OncoSec may report 24-month follow- up data from the Phase 2 investigator-sponsored trial later this year. In the wake of this update, we reiterate our Buy rating and $6 price target. 43% ORR in Phase 2 combo trial. A prior investigator-sponsored Phase 2 combo study of ImmunoPulse IL-12 and Keytruda in 22 metastatic melanoma patients reported positive data. These patients were predicted to have low likelihoods of response to anti-PD-1 monotherapies based on biomarker assays. The results showed a 43% (9/21) ORR at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. There were 24% (5/21) complete responders and 19% (4/22) partial responders. Of note, nine out of the 22 patients enrolled had prior checkpoint inhibitor therapy; ORR for this subset of patients was 33% (3/9). The data showed that intra-tumoral electroporation of interleukin-12 DNA, combined with pembrolizumab, can effectively alter the tumor microenvironment and increase tumor- specific CD8+ T-cells, which drive a systemic anti-tumor immune response. The combo therapy had an acceptable safety profile and was well tolerated." (6/2/2017)
  • 2. Maxim Group analysts commented, "Oncosec’s PISCES study (IL-12 + Keytruda) prepares to launch in June. Merck (MRK – $63.00 – NR) will supply Keytruda on an investigational basis to support the study." (5/18/2017)

Who are some of OncoSec Medical Incorporated's key competitors?

Who are OncoSec Medical Incorporated's key executives?

OncoSec Medical Incorporated's management team includes the folowing people:

  • Avtar S. Dhillon M.D., Independent Chairman of the Board
  • Punit S. Dhillon, President, Chief Executive Officer, Director
  • Richard B. Slansky, Chief Financial Officer
  • Sheela Mohan-Peterson J.D., Chief Legal and Compliance Officer
  • Sharron Gargosky PhD, Chief Clinical and Regulatory Officer
  • Daniel J. O'Connor Esq., Director
  • James Michael DeMesa M.D., Independent Director
  • Annalisa M. Jenkins, Independent Director
  • Anthony E. Maida III, Ph.D., Independent Director

How do I buy OncoSec Medical Incorporated stock?

Shares of OncoSec Medical Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoSec Medical Incorporated's stock price today?

One share of OncoSec Medical Incorporated stock can currently be purchased for approximately $1.25.


MarketBeat Community Rating for OncoSec Medical Incorporated (NASDAQ ONCS)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  188
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OncoSec Medical Incorporated (NASDAQ:ONCS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.33 (326.33% upside)
Consensus Price Target History for OncoSec Medical Incorporated (NASDAQ:ONCS)
Price Target History for OncoSec Medical Incorporated (NASDAQ:ONCS)
Analysts' Ratings History for OncoSec Medical Incorporated (NASDAQ:ONCS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017Maxim GroupReiterated RatingBuy$5.00N/AView Rating Details
7/6/2017Dawson JamesReiterated RatingBuy$5.00HighView Rating Details
6/14/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
6/12/2017HC WainwrightSet Price TargetBuy$6.00LowView Rating Details
12/28/2016Ci CapitalInitiated CoverageBuyN/AView Rating Details
7/21/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for OncoSec Medical Incorporated (NASDAQ:ONCS)
Earnings by Quarter for OncoSec Medical Incorporated (NASDAQ:ONCS)
Earnings History by Quarter for OncoSec Medical Incorporated (NASDAQ ONCS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.22)N/AView Earnings Details
6/1/2017Q3 2017($0.28)($0.22)ViewListenView Earnings Details
10/13/2016Q416($0.32)($0.39)ViewListenView Earnings Details
6/9/2016Q316($0.43)($0.37)ViewN/AView Earnings Details
3/8/2016Q216($0.46)($0.42)ViewN/AView Earnings Details
12/8/2015Q116($0.48)($0.47)ViewN/AView Earnings Details
10/14/2015Q415($0.40)($0.48)ViewListenView Earnings Details
3/12/2015($0.02)($0.02)ViewN/AView Earnings Details
12/8/2014($0.02)($0.02)ViewN/AView Earnings Details
10/13/2014($0.01)($0.01)ViewN/AView Earnings Details
6/16/2014($0.01)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoSec Medical Incorporated (NASDAQ:ONCS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoSec Medical Incorporated (NASDAQ:ONCS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OncoSec Medical Incorporated (NASDAQ:ONCS)
Insider Ownership Percentage: 11.53%
Institutional Ownership Percentage: 8.98%
Insider Trades by Quarter for OncoSec Medical Incorporated (NASDAQ:ONCS)
Institutional Ownership by Quarter for OncoSec Medical Incorporated (NASDAQ:ONCS)
Insider Trades by Quarter for OncoSec Medical Incorporated (NASDAQ:ONCS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/31/2017Punit DhillonInsiderBuy3,000$0.88$2,640.00View SEC Filing  
1/31/2017Punit DhillonInsiderBuy3,000$0.99$2,970.00View SEC Filing  
10/16/2015Punit DhillonCEOBuy10,000$4.25$42,500.00View SEC Filing  
6/10/2015Punit DhillonCEOBuy2,500$6.74$16,850.00View SEC Filing  
3/20/2014Anthony E Maida IIIDirectorBuy22,800$0.81$18,468.00View SEC Filing  
3/19/2014Punit DhillonCEOBuy50,000$0.80$40,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OncoSec Medical Incorporated (NASDAQ:ONCS)
Latest Headlines for OncoSec Medical Incorporated (NASDAQ:ONCS)
Source:
DateHeadline
streetinsider.com logoOncosec Medical (ONCS) Reports Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab
www.streetinsider.com - October 19 at 7:12 AM
finance.yahoo.com logoOncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
finance.yahoo.com - October 19 at 7:12 AM
americanbankingnews.com logoOncoSec Medical Incorporated (ONCS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 7:16 AM
prnewswire.com logoOncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017 - PR Newswire (press release)
www.prnewswire.com - October 14 at 6:26 AM
finance.yahoo.com logoOncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017
finance.yahoo.com - October 14 at 6:26 AM
prnewswire.com logoOncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy ... - PR Newswire (press release)
www.prnewswire.com - October 13 at 7:48 AM
finance.yahoo.com logoOncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research
finance.yahoo.com - October 13 at 7:48 AM
finance.yahoo.com logoOncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research
finance.yahoo.com - October 13 at 7:48 AM
finance.yahoo.com logoIs It The Right Time To Buy OncoSec Medical Incorporated (ONCS)?
finance.yahoo.com - October 13 at 7:48 AM
finance.yahoo.com logoIs It The Right Time To Buy OncoSec Medical Incorporated (ONCS)?
finance.yahoo.com - October 13 at 7:48 AM
finance.yahoo.com logoOncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
finance.yahoo.com - October 12 at 7:53 AM
americanbankingnews.com logoOncoSec Medical Incorporated (ONCS) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - October 11 at 2:08 PM
americanbankingnews.com logoImmunoGen (IMGN) & OncoSec Medical (ONCS) Financial Analysis
www.americanbankingnews.com - October 9 at 10:12 AM
americanbankingnews.com logoOncoSec Medical Inc (ONCS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 8 at 2:56 AM
americanbankingnews.com logoOncoSec Medical Incorporated (ONCS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 4 at 1:22 AM
finance.yahoo.com logoOncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy
finance.yahoo.com - October 2 at 8:29 PM
seekingalpha.com logoOncoSec Medical (ONCS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 7:22 PM
thestreet.com logoOncoSec To Present At The Cantor Fitzgerald Global Healthcare Conference
www.thestreet.com - September 28 at 2:00 AM
americanbankingnews.com logoFinancial Contrast: Jaguar Animal Health (JAGX) vs. OncoSec Medical (ONCS)
www.americanbankingnews.com - September 22 at 2:16 PM
americanbankingnews.com logoHead to Head Contrast: OncoSec Medical (ONCS) vs. TG Therapeutics (TGTX)
www.americanbankingnews.com - September 21 at 8:52 AM
seekingalpha.com logoOncoSec Medical (ONCS) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 7:29 AM
americanbankingnews.com logoOncoSec Medical Incorporated (ONCS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 13 at 2:50 AM
americanbankingnews.com logo Analysts Anticipate OncoSec Medical Incorporated (ONCS) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 9 at 12:22 AM
prnewswire.com logoOncoSec Announces Presentations at Upcoming Investment and ... - PR Newswire (press release)
www.prnewswire.com - September 8 at 6:43 AM
streetinsider.com logoOncosec Medical (ONCS) Names Daniel O'Conner to Board - StreetInsider.com
www.streetinsider.com - September 7 at 7:17 AM
finance.yahoo.com logoOncoSec Announces Presentations at Upcoming Investment and Scientific Conferences
finance.yahoo.com - September 7 at 7:17 AM
finance.yahoo.com logoOncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors
finance.yahoo.com - September 7 at 7:17 AM
americanbankingnews.com logoOncoSec Medical's (ONCS) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - September 4 at 2:32 PM
americanbankingnews.com logoOncoSec Medical Incorporated (ONCS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 19 at 2:42 AM
americanbankingnews.com logoOncoSec Medical Incorporated (NASDAQ:ONCS) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - August 3 at 7:26 AM
americanbankingnews.com logoOncoSec Medical Incorporated (NASDAQ:ONCS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 25 at 11:29 AM
americanbankingnews.com logoOncoSec Medical Incorporated (NASDAQ:ONCS) Short Interest Down 36.0% in June
www.americanbankingnews.com - July 17 at 7:24 AM
americanbankingnews.com logoDawson James Comments on OncoSec Medical Incorporated's FY2017 Earnings (NASDAQ:ONCS)
www.americanbankingnews.com - July 10 at 7:37 AM
americanbankingnews.com logoOncoSec Medical's (ONCS) Buy Rating Reaffirmed at Dawson James
www.americanbankingnews.com - July 9 at 8:06 AM
prnewswire.com logoOncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. - PR Newswire (press release)
www.prnewswire.com - June 13 at 10:40 AM
seekingalpha.com logoOncoSec Medical (ONCS) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 12 at 12:23 AM
streetinsider.com logoOncosec Medical (ONCS) Announces FDA Orphan Drug Designation for Treatment of Unresectable Metastatic ... - StreetInsider.com
www.streetinsider.com - June 9 at 12:57 AM
seekingalpha.com logoOncoSec's (ONCS) CEO Punit Dhillon on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - June 2 at 12:54 AM
streetinsider.com logoOncosec Medical (ONCS) Tops Q3 EPS by 6c - StreetInsider.com - StreetInsider.com
www.streetinsider.com - June 2 at 12:54 AM
prnewswire.com logoOncoSec to Host Third Quarter Financial Conference Call on June 1, 2017 - PR Newswire (press release)
www.prnewswire.com - May 12 at 12:34 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Nvidia, Coty, Fossil, Time Inc ... - Nasdaq
www.nasdaq.com - May 10 at 7:14 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Nvidia, INC Research, Time Inc, Iconix Brand - Nasdaq
www.nasdaq.com - May 10 at 11:53 AM
streetinsider.com logoOncosec (ONCS) Announces Pact with Merck (MRK) to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA ... - StreetInsider.com
www.streetinsider.com - May 10 at 11:53 AM
prnewswire.com logoHow These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:49 PM
prnewswire.com logoOncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017 - PR Newswire (press release)
www.prnewswire.com - May 2 at 4:49 PM
streetinsider.com logoOncosec Medical (ONCS) Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response ... - StreetInsider.com
www.streetinsider.com - April 3 at 9:30 AM
us.rd.yahoo.com logoOncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models
us.rd.yahoo.com - March 21 at 6:53 PM
seekingalpha.com logoOncoSec Medical's (ONCS) CEO Punit Dhillon on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 18 at 12:12 AM
streetinsider.com logoOncosec Medical (ONCS) Enters Technology Access Program Agreement with Inhibrx - StreetInsider.com
www.streetinsider.com - March 14 at 11:33 PM
us.rd.yahoo.com logoOncoSec Announces First Technology Access Program Agreement with Inhibrx
us.rd.yahoo.com - March 14 at 10:30 AM

Social

Chart

OncoSec Medical Incorporated (ONCS) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.